Dr. Joshua Richter and Dr. Peter Forsberg close their discission with thoughtful advice for clinicians regarding the current and future treatment of patients with R/R MM.
Peter Forsberg, MD
Advertisement
Articles by Peter Forsberg, MD
Insights on supportive care measures to minimize or counter common adverse effects for patients with R/R MM taking selinexor-based therapies
Discourse centered around dosing strategies for selinexor-based therapies.
Two subject matter experts discuss keystone trials supporting the use of Selinexor in patients with R/R MM, each with unique dosing structures and different selinexor-based combinations.
Opening their discussion on relapsed/refractory multiple myeloma, Joshua Richter, MD and Peter Forsberg, MD review options for treatment sequencing, initiating treatment, and the mechanism of action for selinexor.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
2
CRT Does Not Improve RFS/OS, Confers High-Grade Toxicity in Cervical Cancer
3
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
4
Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population
5
